Related Experiment Video
Updated: Aug 27, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Septic arthritis induced by Streptococcus pneumoniae occurring in rheumatoid arthritis treated with abatacept and
Kazuya Abe1,2, Yuichi Ishikawa1,3,4, Tatsuro Takahashi1
1Department of Rheumatology, Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan.
Abstract:
Septic arthritis occurs more frequently in elderly patients with rheumatoid arthritis (RA), with Staphylococcus aureus being the most common aetiologic agent. Rarely, Streptococcus pneumoniae (pneumococcus) is the cause of septic arthritis. Biological disease-modifying antirheumatic drugs (bDMARDs) are widely used in RA, but it is unknown whether bDMARDs could be a risk factor for pneumococcal septic arthritis in such patients. Here, we report the case of a patient with RA treated with bDMARDs (abatacept) who developed pneumococcal septic arthritis. The patient is a 64-year-old female complicated with RA for >10 years. She was treated with abatacept and methotrexate and has been in remission for 2 years. She had not received any pneumococcal vaccination. She consulted at our hospital for left ankle arthralgia and fever. Blood culture and puncture of the left ankle joints detected pneumococcus, and the pneumococcal urine antigen test was positive. The patient was diagnosed with pneumococcal septic arthritis, and she recovered after the administration of antibiotics. This is the first case report discussing these circumstances, suggesting that bDMARDs may be a risk of pneumococcal septic arthritis in patients with RA. To prevent this, pneumococcal vaccination should be encouraged in such patients. Furthermore, if RA is in remission, we may consider the spacing or withdrawal of bDMARDs to avoid severe infection.
Insights
Biological disease-modifying antirheumatic drugs (bDMARDs) may increase the risk of pneumococcal septic arthritis in rheumatoid arthritis (RA) patients. Pneumococcal vaccination and careful bDMARD management are recommended for RA patients in remission.
Area of Science:
- Rheumatology
- Infectious Diseases
- Clinical Medicine
Background:
- Rheumatoid arthritis (RA) patients, especially the elderly, are susceptible to septic arthritis, commonly caused by Staphylococcus aureus.
- Biological disease-modifying antirheumatic drugs (bDMARDs) are frequently used for RA management, but their role in specific infections like pneumococcal septic arthritis remains unclear.
- Streptococcus pneumoniae (pneumococcus) is a rare but serious cause of septic arthritis.
Observation:
- A 64-year-old female RA patient treated with bDMARDs (abatacept) and methotrexate, who was in remission and unvaccinated against pneumococcus, developed pneumococcal septic arthritis.
- The patient presented with left ankle arthralgia and fever, with positive blood and synovial fluid cultures for pneumococcus.
- Pneumococcal urinary antigen test was also positive, confirming the diagnosis.
Findings:
- This case report details the first instance of pneumococcal septic arthritis in an RA patient treated with abatacept.
- The findings suggest a potential risk association between bDMARD use and pneumococcal septic arthritis in RA patients.
- The patient successfully recovered after antibiotic treatment.
Implications:
- Encouraging pneumococcal vaccination is crucial for RA patients on bDMARDs.
- Consideration should be given to spacing or discontinuing bDMARDs in RA patients who have achieved remission to mitigate the risk of severe infections.
- Further research is warranted to elucidate the precise relationship between bDMARDs and pneumococcal infections in RA.
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease III: Medical Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Endocarditis III: Medical Management

